Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors
Regular price
€190.90
14 days return policy
Shipping & Delivery
biological
book
cancer
Category=PNN
Category=PS
Category=PSE
characteristics
discovered
disorders
effective
eq_bestseller
eq_isMigrated=1
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_science
forms
glycogen
inhibitors
interest
kinase
little
many
much potential
nature
neurogenerative
new
potential
researchers
synthase
treatments
twentyfive
years
Product details
- ISBN 9780471770015
- Weight: 658g
- Dimensions: 161 x 243mm
- Publication Date: 03 Nov 2006
- Publisher: John Wiley & Sons Inc
- Publication City/Country: US
- Product Form: Hardback
Secure
checkout
Fast Shipping
Easy returns
Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.
ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors.
ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured scientist at the Medicinal Chemistry Institute.
MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Women's Hospital and the Harvard Medical School.
